Mikrogen

Executive Summary

Mikrogen is a privately held German biotechnology company that has established itself as a global market leader in infectious serology within the in-vitro diagnostics (IVD) sector. Founded in 1988, the company develops and manufactures automated platforms for immunoassays and molecular diagnostics, and is fully IVDR certified, underscoring its commitment to regulatory compliance and quality. With a focus on preserving health through safe diagnostics, Mikrogen serves a broad base of customers worldwide, leveraging its expertise in system solutions that integrate reagents, instruments, and software. The company's long track record and specialized niche position it as a stable player in the growing IVD market, which is driven by increasing demand for infectious disease testing and automation in clinical laboratories. While Mikrogen operates in a competitive landscape, its deep domain knowledge and established customer relationships provide a solid foundation for continued growth.

Upcoming Catalysts (preview)

• Q3 2026Launch of Next-Generation Automated Molecular Diagnostics Platform70% success
• Q4 2026Expansion into Asian and Latin American Markets via New Distribution Partnerships60% success
• TBDStrategic Acquisition or Licensing Deal to Broaden Infectious Disease Test Menu40% success